Nordicus Partners Corporation Announces Key Milestone in Development of Orocidin’s Breakthrough Treatment for Periodontitis

Rhea-AI Summary

Nordicus Partners (NORD) announced that its subsidiary, Orocidin A/S, will begin its toxicity program for Orocidin (QR-01) in January 2025. The program is expected to be completed by Q3 2025, enabling the launch of the first pilot efficacy study in patients by year-end.

Orocidin is a proprietary treatment for periodontitis that addresses three key challenges: inflammation reduction, bacterial infection elimination, and bone/teeth regeneration. The company has filed patent applications to protect the product's innovative design.

The development represents a significant milestone in bringing this dental health solution to market, targeting an unmet medical need.

Positive

• Patent applications filed for innovative periodontitis treatment
• Clear development timeline established with toxicity program starting January 2025
• Product addresses multiple aspects of periodontitis treatment (inflammation, infection, regeneration)

Negative

• No revenue generation expected in near term as product is still in early development phase
• Success of toxicity program and subsequent clinical trials not guaranteed
• Significant time and resources required before potential market approval

BEVERLY HILLS, California, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announced today that its subsidiary, Orocidin A/S, will initiate its toxicity program for Orocidin (QR-01) in January 2025. The program is expected to conclude by the third quarter of 2025, paving the way for Orocidin to launch its first pilot efficacy study in patients by the end of 2025.

Orocidin (QR-01) is a proprietary, internally developed product that offers a novel solution for treating periodontitis. The product addresses three critical challenges associated with the disease: reducing inflammation, eradicating bacterial infections, and promoting bone (teeth) regeneration. Patent applications have been submitted to protect its innovative design.

“We are very pleased that Orocidin has reached this critical stage of development, bringing us closer to demonstrating the efficacy of our solution and addressing a significant unmet need in dental health,” said Allan Wehnert, Founder and CEO of Orocidin. “Orocidin represents Nordicus’ commitment to advancing innovative solutions that have the potential to improve lives and create value for stakeholders.”

For further information, contact:

Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666 0750
Email hr@nordicuspartners.com

Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401

About Nordicus Partners Corporation

Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company developing next-generation therapies for periodontitis and 100% of Bio-Convert ApS, a Danish preclinical-stage biotech company dedicated to revolutionizing the treatment of oral leukoplakia. For more information about Nordicus, please visit: www.nordicuspartners.com, and follow us on LinkedIn, X, Threads and BlueSky.

Cautionary Note Regarding Forward-Looking Statements:

This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 

FAQ

When will Nordicus (NORD) begin toxicity testing for Orocidin?

Nordicus will begin toxicity testing for Orocidin (QR-01) in January 2025.

What are the three main benefits of Orocidin's periodontitis treatment?

Orocidin addresses three key challenges: reducing inflammation, eradicating bacterial infections, and promoting bone (teeth) regeneration.

When does NORD expect to complete the Orocidin toxicity program?

The toxicity program is expected to conclude by the third quarter of 2025.

When will NORD begin the first pilot efficacy study for Orocidin?

Nordicus plans to launch the first pilot efficacy study for Orocidin by the end of 2025.

Has Nordicus filed patents for Orocidin's periodontitis treatment?

Yes, Nordicus has submitted patent applications to protect Orocidin's innovative design.